← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $610B	3,732	-60	-2%	$280B
2	2 Merck MRK $358B	3,181	-57	-2%	$206B
3	3 AbbVie ABBV $501B	3,141	-30	-0.9%	$197B
4	4 Pfizer PFE $168B	3,105	-163	-5%	$162B
5	5 Bristol-Myers Squibb BMY $124B	2,542	-60	-2%	$111B
6	6 Amgen AMGN $235B	2,435	-66	-3%	$98.3B
7	7 Gilead Sciences GILD $195B	1,737	-31	-2%	$86.1B
8	8 Regeneron Pharmaceuticals REGN $82B	1,191	+33	+3%	$76.1B
9	9 Novartis NVS $286B	1,180	-2	-0.2%	$15.2B
10	10 AstraZeneca AZN $259B	1,055	-7	-0.7%	$35B
11	11 GSK GSK $98.2B	808	-5	-0.6%	$9.68B
12	12 DELISTED Exact Sciences EXAS	584	+34	+6%	$11.2B
13	SGEN 13 DELISTED Seagen Inc. Common Stock SGEN	575	+38	+7%	$33.6B
14	14 Incyte INCY $23B	551	-7	-1%	$15.8B
15	15 Jazz Pharmaceuticals JAZZ $13.9B	471	-14	-3%	$8.31B
16	16 Lantheus LNTH $6.53B	387	+23	+6%	$5.54B
17	17 Halozyme HALO $13.8B	386	-36	-9%	$4.77B
18	18 Exelixis EXEL $15.6B	365	-22	-6%	$5.45B
19	19 Natera NTRA $58.3B	327	+51	+18%	$6.01B
20	20 Takeda Pharmaceutical TAK $62.1B	300	+19	+7%	$1.38B
21	21 Qiagen QGEN $9.53B	287	-9	-3%	$6.24B
22	22 BioNTech BNTX $22.7B	281	-38	-12%	$4.88B
23	23 Guardant Health GH $22.3B	279	-11	-4%	$2.17B
24	24 NeoGenomics NEO $2.22B	256	+14	+6%	$2.02B
25	25 Veracyte VCYT $3.57B	232	+10	+5%	$1.74B